AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 29898902 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide (≤1.8 mg daily)
Number of subjects: 9360
Study 29898902 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 9360
Study 29898902 — intervention group
Group type: EXPERIMENTAL
Intervention: Liraglutide
Number of subjects: 9360
Study 26429360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine (loading dose, 1 μg/kg; maintenance dose, 0.6 μg/kg/h)
Number of subjects: 116
Study 26429360 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose dexmedetomidine (loading dose, 0.6 μg/kg; maintenance dose, 0.3 μg/kg/h)
Number of subjects: 116
Study 26429360 — intervention group
Group type: COMPARATOR
Intervention: Control group (0.9% saline as placebo)
Number of subjects: 116
Study 26429360 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose dexmedetomidine
Number of subjects: 116
Study 24477765 — intervention group
Group type: COMPARATOR
Intervention: Visual targets
Number of subjects: 20
Study 24477765 — intervention group
Group type: COMPARATOR
Intervention: Touch targets
Number of subjects: 20
Study 24477765 — intervention group
Group type: COMPARATOR
Intervention: Anticipation errors
Number of subjects: 20
Study 22870700 — intervention group
Group type: EXPERIMENTAL
Intervention: Propranolol with 1064 nm Nd:YAG laser (A group)
Number of subjects: 97
Study 22870700 — intervention group
Group type: COMPARATOR
Intervention: 1064 nm Nd:YAG laser (B group)
Number of subjects: 97
Study 22870700 — intervention group
Group type: COMPARATOR
Intervention: Propranolol (C group)
Number of subjects: 97
Study 20701511 — intervention group
Group type: EXPERIMENTAL
Intervention: Spinal anaesthesia
Number of subjects: 38
Study 20701511 — intervention group
Group type: COMPARATOR
Intervention: Sedation
Number of subjects: 38
Study 17334829 — intervention group
Group type: EXPERIMENTAL
Intervention: IRT based scale combining MHAQ and PF10
Number of subjects: 339
Study 17334829 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAQ
Number of subjects: 339
Study 17334829 — intervention group
Group type: EXPERIMENTAL
Intervention: PF10
Number of subjects: 339
Study 17334829 — intervention group
Group type: EXPERIMENTAL
Intervention: MHAQ and PF10
Number of subjects: 339
Study 15606570 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous octreotide 100 microg
Number of subjects: 51
Study 15606570 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 12744870 — intervention group
Group type: EXPERIMENTAL
Intervention: CF‐BS‐ETEC vaccine
Number of subjects: 158
Study 12744870 — intervention group
Group type: COMPARATOR
Intervention: Placebo (E. coli K12)
Number of subjects: 158
Study 10471225 — intervention group
Group type: EXPERIMENTAL
Intervention: Not available
Number of subjects: 0
Study 7755164 — intervention group
Group type: EXPERIMENTAL
Intervention: β-lactam/β-lactamase inhibitor agents (ampicillin/sulbactam, ticarcillin/clavulanate, piperacillin/tazobactam)
Number of subjects: 0
Study 7755164 — intervention group
Group type: COMPARATOR
Intervention: piperacillin/tazobactam
Number of subjects: 0
Study 7755164 — intervention group
Group type: COMPARATOR
Intervention: aminoglycoside plus antianaerobic therapy
Number of subjects: 0
Study 7755164 — intervention group
Group type: COMPARATOR
Intervention: second-generation cephalosporin or aminoglycoside plus antianaerobic comparators
Number of subjects: 0
Study 1852084 — intervention group
Group type: EXPERIMENTAL
Intervention: RIT 4237 bovine rotavirus vaccine
Number of subjects: 252
Study 1852084 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 252
Study 7017311 — intervention group
Group type: EXPERIMENTAL
Intervention: Tympanostomy tubes
Number of subjects: 0
Study 7017311 — intervention group
Group type: COMPARATOR
Intervention: Conventional antibiotic therapy
Number of subjects: 0
Study 31535299 — intervention group
Group type: EXPERIMENTAL
Intervention: Surgery for regional lymph nodes (Selective Lymphadenectomy)
Number of subjects: 0
Study 31535299 — intervention group
Group type: EXPERIMENTAL
Intervention: Nodal intervention
Number of subjects: 0
Study 31535299 — intervention group
Group type: EXPERIMENTAL
Intervention: MSLT-I, MSLT-II, DeCOG trials
Number of subjects: 0
Study 30984985 — intervention group
Group type: EXPERIMENTAL
Intervention: Subthalamic nucleus (STN) deep brain stimulation (DBS)
Number of subjects: 12
Study 30984985 — intervention group
Group type: EXPERIMENTAL
Intervention: Globus pallidus interna (GPi) deep brain stimulation (DBS)
Number of subjects: 12
Study 28336345 — intervention group
Group type: EXPERIMENTAL
Intervention: Irish set dance classes (1.5 hours/week for 10 weeks + home dance program 20 minutes, 3 times/week)
Number of subjects: 90
Study 28336345 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 90
Study 27264413 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mg/day atorvastatin
Number of subjects: 118
Study 27264413 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg/day pitavastatin
Number of subjects: 118
Study 27264413 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg/day pravastatin
Number of subjects: 118
Study 27264413 — intervention group
Group type: EXPERIMENTAL
Intervention: 30 mg/day fluvastatin
Number of subjects: 118
Study 27264413 — intervention group
Group type: EXPERIMENTAL
Intervention: Moderate-intensity statin therapy
Number of subjects: 118
Study 27264413 — intervention group
Group type: COMPARATOR
Intervention: Low-intensity statin therapy
Number of subjects: 118
Study 24754318 — intervention group
Group type: EXPERIMENTAL
Intervention: VNS + BMP
Number of subjects: 112
Study 24754318 — intervention group
Group type: COMPARATOR
Intervention: BMP
Number of subjects: 112
Study 23012427 — intervention group
Group type: EXPERIMENTAL
Intervention: Ketamine (NMDA receptor antagonist)
Number of subjects: 0
Study 19442931 — intervention group
Group type: EXPERIMENTAL
Intervention: Indomethacin (100 mg, oral, 90 min)
Number of subjects: 14
Study 19442931 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study 18161398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin (500 mg twice a day)
Number of subjects: 63
Study 18161398 — intervention group
Group type: COMPARATOR
Intervention: Insulin
Number of subjects: 63
Study 18161398 — intervention group
Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 63
Study 14693528 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 1,395 mg BID
Number of subjects: 78
Study 14693528 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 1,860 mg BID
Number of subjects: 78
Study 14693528 — intervention group
Group type: COMPARATOR
Intervention: Amprenavir 1,200 mg BID
Number of subjects: 78
Study 14693528 — intervention group
Group type: EXPERIMENTAL
Intervention: All three regimens (GW433908 and amprenavir)
Number of subjects: 78
Study 14693528 — intervention group
Group type: EXPERIMENTAL
Intervention: GW433908 groups
Number of subjects: 78
Study 12512665 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine with epinephrine
Number of subjects: 681
Study 12512665 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine plain
Number of subjects: 681
Study 9835204 — intervention group
Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis patients
Number of subjects: 30
Study 9835204 — intervention group
Group type: COMPARATOR
Intervention: Other vascular diseases (control)
Number of subjects: 30
Study 9835204 — intervention group
Group type: COMPARATOR
Intervention: Autoimmune diseases (control)
Number of subjects: 30
Study 9835204 — intervention group
Group type: COMPARATOR
Intervention: Normal healthy individuals (control)
Number of subjects: 30
Study 9835204 — intervention group
Group type: EXPERIMENTAL
Intervention: Collagenase treatment of aorta
Number of subjects: 30
Study 9835204 — intervention group
Group type: EXPERIMENTAL
Intervention: Takayasu's arteritis patients' sera
Number of subjects: 30
Study 8120290 — intervention group
Group type: EXPERIMENTAL
Intervention: 1987‐88 NFCS 24‐hour recall procedures
Number of subjects: 697
Study 8120290 — intervention group
Group type: COMPARATOR
Intervention: 1977‐78 NFCS 24‐hour recall procedures
Number of subjects: 697
Study 2553325 — intervention group
Group type: COMPARATOR
Intervention: Carbidopa
Number of subjects: 10
Study 2553325 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 2553325 — intervention group
Group type: EXPERIMENTAL
Intervention: Atrial natriuretic factor infusion
Number of subjects: 10
Study 776194 — intervention group
Group type: EXPERIMENTAL
Intervention: Aptocaine 1%, 2%, 3%
Number of subjects: 55
Study 776194 — intervention group
Group type: COMPARATOR
Intervention: Lignocaine 2%
Number of subjects: 55
Study 776194 — intervention group
Group type: COMPARATOR
Intervention: Bupivacaine 0.5%
Number of subjects: 55
Study 776194 — intervention group
Group type: EXPERIMENTAL
Intervention: Mepivacaine 1%, 2%, 3%
Number of subjects: 55
Study 776194 — intervention group
Group type: COMPARATOR
Intervention: Prilocaine 1%, 2%, 3%
Number of subjects: 55
Study 30654328 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally enhanced messages via smartphone application
Number of subjects: 82
Study 30654328 — intervention group
Group type: COMPARATOR
Intervention: Control group (usual DAQI messages)
Number of subjects: 82
Study 30654328 — intervention group
Group type: EXPERIMENTAL
Intervention: Behaviourally enhanced messages
Number of subjects: 82
Study 30654328 — intervention group
Group type: EXPERIMENTAL
Intervention: Both message formats (behaviourally enhanced and usual DAQI messages)
Number of subjects: 82
Study 28304211 — intervention group
Group type: EXPERIMENTAL
Intervention: EMD
Number of subjects: 39
Study 28304211 — intervention group
Group type: EXPERIMENTAL
Intervention: BONE+EMD
Number of subjects: 39
Study 28304211 — intervention group
Group type: COMPARATOR
Intervention: BONE
Number of subjects: 39
Study 25414266 — intervention group
Group type: EXPERIMENTAL
Intervention: Voriconazole
Number of subjects: 379
Study 25414266 — intervention group
Group type: COMPARATOR
Intervention: Amphotericin B (AmB)
Number of subjects: 379
Study 23506973 — intervention group
Group type: EXPERIMENTAL
Intervention: Peer companionship intervention for older adults
Number of subjects: 0
Study 21444874 — intervention group
Group type: EXPERIMENTAL
Intervention: MRI screening
Number of subjects: 1275
Study 21444874 — intervention group
Group type: COMPARATOR
Intervention: Comparison group (conventional screening)
Number of subjects: 1275
Study 19801069 — intervention group
Group type: EXPERIMENTAL
Intervention: Real rTMS
Number of subjects: 13
Study 19801069 — intervention group
Group type: COMPARATOR
Intervention: Sham rTMS
Number of subjects: 13
Study 16688374 — intervention group
Group type: EXPERIMENTAL
Intervention: Acne Dressing
Number of subjects: 20
Study 16688374 — intervention group
Group type: COMPARATOR
Intervention: Skin tapes
Number of subjects: 20
Study 15358983 — intervention group
Group type: EXPERIMENTAL
Intervention: 300 mg L-dopa
Number of subjects: 33
Study 15358983 — intervention group
Group type: EXPERIMENTAL
Intervention: 1.25 mg bromocriptine
Number of subjects: 33
Study 15358983 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 33
Study 11399369 — intervention group
Group type: EXPERIMENTAL
Intervention: iodixanol 270 mg I/ml
Number of subjects: 111
Study 11399369 — intervention group
Group type: COMPARATOR
Intervention: iohexol 300 mg I/ml
Number of subjects: 111
Study 7902901 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective episiotomy (limited to specified maternal or fetal indications)
Number of subjects: 2606
Study 7902901 — intervention group
Group type: COMPARATOR
Intervention: Routine episiotomy (following the hospital's previous policy)
Number of subjects: 2606
Study 7902901 — intervention group
Group type: EXPERIMENTAL
Intervention: Selective episiotomy
Number of subjects: 2606
Study 2824706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin (200 mg/m2 divided in five daily doses) and vinblastine (7.5 mg/m2 as a continuous IV infusion over five days) followed by radiation therapy
Number of subjects: 47
Study 2824706 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and vinblastine followed by observation only (no radiation)
Number of subjects: 47
Study 2824706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiation therapy
Number of subjects: 47
Study 2824706 — intervention group
Group type: COMPARATOR
Intervention: Cisplatin and vinblastine followed by observation only (no radiation) for responders
Number of subjects: 47
Study 2824706 — intervention group
Group type: EXPERIMENTAL
Intervention: Cisplatin and vinblastine followed by radiation therapy for nonresponders
Number of subjects: 47
Study 30990213 — intervention group
Group type: EXPERIMENTAL
Intervention: Bread fortified with 2.3 g PS and 228 mg CC (PS-C)
Number of subjects: 75
Study 30990213 — intervention group
Group type: COMPARATOR
Intervention: Bread fortified with placebo (PL) and curcumin (CC) (PL-C)
Number of subjects: 75
Study 28847641 — intervention group
Group type: EXPERIMENTAL
Intervention: SD OCT-based risk assessment model for new onset of CP-visible GA
Number of subjects: 317
Study 28847641 — intervention group
Group type: EXPERIMENTAL
Intervention: SD OCT-based risk assessment model for central GA
Number of subjects: 317
Study 26867333 — intervention group
Group type: EXPERIMENTAL
Intervention: Fennel tea (5 grams of dried fennel fruit in 130 mL boiled water, twice per day)
Number of subjects: 159
Study 26867333 — intervention group
Group type: COMPARATOR
Intervention: Control group (equal quantity of water, twice per day)
Number of subjects: 159
Study 23196419 — intervention group
Group type: EXPERIMENTAL
Intervention: NAVA
Number of subjects: 10
Study 23196419 — intervention group
Group type: COMPARATOR
Intervention: PSV30
Number of subjects: 10
Study 23196419 — intervention group
Group type: COMPARATOR
Intervention: PSV1
Number of subjects: 10
Study 21710343 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose N-acetylcysteine (N-ACC) 2 × 1200 mg/d for 48 h with optimal hydration
Number of subjects: 251
Study 21710343 — intervention group
Group type: COMPARATOR
Intervention: Placebo plus optimal hydration
Number of subjects: 251
Study 21710343 — intervention group
Group type: EXPERIMENTAL
Intervention: N-ACC and placebo groups
Number of subjects: 251
Study 18473689 — intervention group
Group type: EXPERIMENTAL
Intervention: Cell phone‐based diabetes management software (WellDoc Communications, Inc.)
Number of subjects: 30
Study 18473689 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard care)
Number of subjects: 30
Study 16524858 — intervention group
Group type: EXPERIMENTAL
Intervention: Levothyroxine (LT4) therapy
Number of subjects: 33
Study 16524858 — intervention group
Group type: COMPARATOR
Intervention: Control group (no LT4 therapy)
Number of subjects: 33
Study 15631797 — intervention group
Group type: EXPERIMENTAL
Intervention: Cefdinir 100 mg, orally, three times a day for 7-14 days
Number of subjects: 64
Study 15631797 — intervention group
Group type: COMPARATOR
Intervention: Cefaclor 500 mg, orally, three times a day for 7-14 days
Number of subjects: 64
Study 11139111 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS value of 60
Number of subjects: 45
Study 11139111 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS value of 50
Number of subjects: 45
Study 11139111 — intervention group
Group type: EXPERIMENTAL
Intervention: BIS value of 40
Number of subjects: 45
Study 11139111 — intervention group
Group type: COMPARATOR
Intervention: Control (BIS values 60 and 50)
Number of subjects: 45
Study 9379067 — intervention group
Group type: EXPERIMENTAL
Intervention: Patient-controlled analgesia (PCA)
Number of subjects: 6000
Study 9379067 — intervention group
Group type: COMPARATOR
Intervention: Patient-controlled analgesia (PCA) with background opioid infusion
Number of subjects: 6000
Study 8269563 — intervention group
Group type: EXPERIMENTAL
Intervention: Bupivacaine 0.25%
Number of subjects: 28
Study 8269563 — intervention group
Group type: COMPARATOR
Intervention: Saline 0.9%
Number of subjects: 28
Study 2863392 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg. dezocine
Number of subjects: 149
Study 2863392 — intervention group
Group type: EXPERIMENTAL
Intervention: 15 mg. dezocine
Number of subjects: 149
Study 2863392 — intervention group
Group type: COMPARATOR
Intervention: 10 mg. morphine
Number of subjects: 149
Study 2863392 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups (dezocine and morphine)
Number of subjects: 149
Study 31295275 — intervention group
Group type: EXPERIMENTAL
Intervention: BLS education with web-based education in cardiovascular diseases (CVD)
Number of subjects: 2623
Study 31295275 — intervention group
Group type: COMPARATOR
Intervention: BLS education without web-based education in CVD
Number of subjects: 2623
Study 29176383 — intervention group
Group type: EXPERIMENTAL
Intervention: Jump Interval Training (JIT) - performed twice per week, consisting of 4-6 bouts of continuous vertical jumping (30 seconds) with 5-minute intervals
Number of subjects: 18
Study 29176383 — intervention group
Group type: COMPARATOR
Intervention: Continuous endurance training (40-minute running at 70% of peak aerobic velocity, 3 times per week for 4 weeks)
Number of subjects: 18
Study 27279266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 1.5 mg
Number of subjects: 144
Study 27279266 — intervention group
Group type: EXPERIMENTAL
Intervention: Dulaglutide 0.75 mg
Number of subjects: 144
Study 27279266 — intervention group
Group type: COMPARATOR
Intervention: Glargine
Number of subjects: 144
Study 24485479 — intervention group
Group type: EXPERIMENTAL
Intervention: Clonidine (0.15 mg orally)
Number of subjects: 40
Study 24485479 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 22961867 — intervention group
Group type: EXPERIMENTAL
Intervention: Acute oral antioxidant cocktail (AOC) consisting of vitamin C, E, and α-lipoic acid
Number of subjects: 10
Study 22961867 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10
Study 20591671 — intervention group
Group type: EXPERIMENTAL
Intervention: BPTB reconstruction
Number of subjects: 18
Study 20591671 — intervention group
Group type: EXPERIMENTAL
Intervention: ST/G reconstruction
Number of subjects: 18
Study 20591671 — intervention group
Group type: EXPERIMENTAL
Intervention: Intact contralateral leg
Number of subjects: 18
Study 20591671 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 18
Study 18093299 — intervention group
Group type: COMPARATOR
Intervention: Standard cryotherapy (intermittent ice applications with compression)
Number of subjects: 120
Study 18093299 — intervention group
Group type: EXPERIMENTAL
Intervention: Cryokinetic treatment (intermittent ice applications with compression and therapeutic exercise)
Number of subjects: 120
Study 16128933 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 40 mg
Number of subjects: 675
Study 16128933 — intervention group
Group type: EXPERIMENTAL
Intervention: Esomeprazole 20 mg
Number of subjects: 675
Study 16128933 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 675
Study 12150230 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure and typicality
Number of subjects: 0
Study 12150230 — intervention group
Group type: EXPERIMENTAL
Intervention: Self-disclosure and category salience
Number of subjects: 0
Study 11155139 — intervention group
Group type: EXPERIMENTAL
Intervention: Systemic interferon‐alpha‐2A treatment
Number of subjects: 79
Study 11155139 — intervention group
Group type: COMPARATOR
Intervention: Prednisolone enemas
Number of subjects: 79
Study 11155139 — intervention group
Group type: EXPERIMENTAL
Intervention: Low‐field magnetic resonance imaging
Number of subjects: 79
Study 8788287 — intervention group
Group type: EXPERIMENTAL
Intervention: Whey-based formula
Number of subjects: 24
Study 1319732 — intervention group
Group type: EXPERIMENTAL
Intervention: FUdR-C8 ester in Lipiodol
Number of subjects: 103
Study 1319732 — intervention group
Group type: COMPARATOR
Intervention: Water-soluble adriamycin emulsified in Lipiodol (control)
Number of subjects: 103
Study 6711479 — intervention group
Group type: EXPERIMENTAL
Intervention: Hydrogenated fat diet
Number of subjects: 8
Study 6711479 — intervention group
Group type: COMPARATOR
Intervention: Nonhydrogenated fat diet
Number of subjects: 8
Study 31375102 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluticasone furoate/vilanterol (FF/VI)
Number of subjects: 0
Study 31375102 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study 29111889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement containing raspberry ketone, capsaicin, caffeine, garlic, and Citrus aurantium (EXP)
Number of subjects: 36
Study 29111889 — intervention group
Group type: EXPERIMENTAL
Intervention: Dietary supplement (EXP)
Number of subjects: 36
Study 29111889 — intervention group
Group type: COMPARATOR
Intervention: Placebo (PLA)
Number of subjects: 36
Study 26893135 — intervention group
Group type: EXPERIMENTAL
Intervention: 9-month pharmacist intervention
Number of subjects: 390
Study 26893135 — intervention group
Group type: EXPERIMENTAL
Intervention: 24-month pharmacist intervention
Number of subjects: 390
Study 26893135 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control)
Number of subjects: 390
Study 24694358 — intervention group
Group type: EXPERIMENTAL
Intervention: Vicco(®) turmeric cream (VTC) applied five times a day
Number of subjects: 50
Study 24694358 — intervention group
Group type: COMPARATOR
Intervention: Johnson's(®) baby oil (Control) applied five times a day
Number of subjects: 50
Study 22338101 — intervention group
Group type: EXPERIMENTAL
Intervention: Mindfulness-based stress reduction (MBSR) intervention
Number of subjects: 110
Study 22338101 — intervention group
Group type: COMPARATOR
Intervention: Treatment-as-usual control
Number of subjects: 110
Study 20706632 — intervention group
Group type: EXPERIMENTAL
Intervention: Peptide vaccine (1 or 4 mg)
Number of subjects: 24
Study 20706632 — intervention group
Group type: COMPARATOR
Intervention: Control (placebo)
Number of subjects: 24
Study 17510493 — intervention group
Group type: EXPERIMENTAL
Intervention: L-lysine (2.64 g per day) and L-arginine (2.64 g per day)
Number of subjects: 108
Study 15982133 — intervention group
Group type: EXPERIMENTAL
Intervention: Fixation distractors
Number of subjects: 0
Study 15982133 — intervention group
Group type: COMPARATOR
Intervention: Peripheral distractors
Number of subjects: 0
Study 11918580 — intervention group
Group type: EXPERIMENTAL
Intervention: Natural vegetable fats (rape seed and palm fats)
Number of subjects: 20
Study 10341866 — intervention group
Group type: COMPARATOR
Intervention: Carbimazole for 18 months
Number of subjects: 134
Study 10341866 — intervention group
Group type: EXPERIMENTAL
Intervention: Carbimazole for 42 months
Number of subjects: 134
Study 7861489 — intervention group
Group type: EXPERIMENTAL
Intervention: Ungated lithotripsy
Number of subjects: 82